Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 989-1007 , December 2008

Radio-iodine therapy in differentiated thyroid cancer: indications and procedures

  • Christoph Reiners, MD (Professor of Nuclear Medicine and Director)

      Affiliations

    • Corresponding Author InformationCorresponding author. Tel.: +49 931 20 35868; Fax: +49 931 201 35247.

References 

  1. Cooper DS, Doherty GM, Haugen BR, et al. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2006;16:1–33
  2. AACE/AME Task Force on Thyroid Nodules . American Association of Clinical Endocrinologists and Associazione Medici Endocrinologi Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocrine Practice. 2006;12:63–102
  3. Pacini F, Schlumberger M, Harmer C, et al. Post-surgical use of radioiodine (I-131) in patients with papillary and follicular thyroid cancer and the issue of remnant ablation: a consensus report. European Journal of Endocrinology. 2005;153:651–659
  4. Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. European Journal of Endocrinology. 2006;154:787–803
  5. Luster M, Clarke SE, Dietlein M, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35:1941–1959
  6. Sawka AM, Thephamongkhol K, Brouwers M, et al. Clinical review 170: A systematic review and metaanalysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2004;89:3668–3676
  7. Pelizzo MR, Boschin IM, Toniato A, et al. Natural history, diagnosis, treatment and outcome of papillary thyroid microcarcinoma (PTMC): a monoinstitutional 12-year experience. Nuclear Medicine Communications. 2004;25:547–552
  8. Machens A, Holzhausen HJ, Dralle H. The prognostic value of primary tumor size in papillary and follicular thyroid carcinoma. Cancer. 2005;103:2269–2273
  9. Dietlein M, Dressler J, Escher W, et al. Procedure guidelines for radioiodine therapy of differentiated thyroid cancer (version 3). Nuklearmedizin. 2007;46:213–219[German]
  10. Rahbar K, Hutzenlaub V, Fischer RJ, et al. Comparative study on the radioiodine ablation in small papillary and follicular thyroid carcinomas (≤1cm). Nuklearmedizin, in press.
  11. Lassmann M, Luster M, Hänscheid H, et al. Impact of (131)I diagnostic activities on the biokinetics of thyroid remnants. Journal of Nuclear Medicine. 2004;45:619–625
  12. Freudenberg L, Jentzen W, Görges R, et al. 124I-positron emission tomography dosimetry in advanced differentiated thyroid cancer: therapeutic impact. Nuklearmedizin 46, in press.
  13. Serhal DI, Nasrallah MP, Arafah BM. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2004;89:3285–3289
  14. Pacini F, Ladenson PW, Schlumberger M, et al. Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. The Journal of Clinical Endocrinology and Metabolism. 2006;91:926–932
  15. Haenscheid H, Lassmann M, Luster M, et al. Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. Journal of Nuclear Medicine. 2006;47:648–654
  16. Luster M, Sherman SI, Skarulis MC, et al. Comparison of radioiodine biokinetics following the administration of Recombinant Human Thyroid Stimulating Hormone (rhTSH) and after thyroid hormone withdrawal in thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:1371–1377
  17. Löffler M, Weckesser M, Franzius C, et al. Iodine excretion during stimulation with rhTSH in differentiated thyroid carcinoma. Nuklearmedizin. 2003;42:240–243
  18. Mernagh P, Campell S, Dietlein M, et al. Cost-effectiveness of using recombinant human TSH (rhTSH) prior to radioiodine therapy ablation for thyroid cancer, compared with treating patients in a hypothyroid state: the German perspective. European Journal of Endocrinology. 2006;155:405–414
  19. Duntas LH, Biondi B. Short-term hypothyroidism after Levothyroxine-withdrawal in patients with differentiated thyroid cancer: clinical and quality of life consequences. European Journal of Endocrinology. 2007;156:13–19
  20. Tuttle RM, Brokhin M, Omry G, et al. Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. Journal of Nuclear Medicine. 2008;49:764–770
  21. Barbaro D, Boni G, Meucci G, et al. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation. The Journal of Clinical Endocrinology. 2003;88:4110–4115
  22. Pilli T, Brianzoni E, Capoccetti F, et al. A comparison of 1850 (50 mCi) and 3700 (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. The Journal of Clinical Endocrinology and Metabolism. 2007;92:3542–3546
  23. Barbaro D, Boni G, Meucci G, et al. Recombinant human thyroid-stimulating hormone is effective for radioiodine ablation of post-surgical thyroid remnants. Nuclear Medicine Communications. 2006;27:627–632
  24. Pacini , Molinari E, Castagna MG, et al. Ablation of thyroid remnants with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. The Journal of Clinical Endocrinology and Metabolism. 2002;87:4063–4068
  25. Lassmann M, Hänscheid H. Spatial dose mapping for individualizing radioiodine treatment. Journal of Nuclear Medicine. 2007;48:2–4
  26. Lassmann M, Hänscheid H, Chiesa C, et al. EANM Dosimetry Committee series on standard operational procedures for pre-therapeutic dosimetry I: blood and bone marrow dosimetry in differentiated thyroid cancer therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2008;35:1405–1412
  27. Benua RS, Cicale NR, Sonenberg M, et al. The relation of radioiodine dosimetry to results and complications in the treatment of metastatic thyroid cancer. AJR. American Journal of Roentgenology. 1962;87:171
  28. Maxon HR, Thomas SR, Boehringer A, et al. Low iodine diet in 131I ablation of thyroid remnants. Clinical Nuclear Medicine. 1983;8:123–126
  29. Schlumberger M, De Vathaire F, Ceccarelli C, et al. Exposure to radioactive iodine-131 for scintigraphy or therapy does not preclude pregnancy in thyroid cancer patients. Journal of Nuclear Medicine. 1996;37:606–612
  30. Krassas GE, Pontikides N. Gonadal effect of radiation from 131I in male patients with thyroid carcinoma. Archives of Andrology. 2005;51:171–175
  31. Ceccarelli C, Battisti P, Gasperi M, et al. Radiation dose to the testes after 131I therapy for ablation of postsurgical remnants in patients with differentiated thyroid cancer. Journal of Nuclear Medicine. 1999;40:1716–1721
  32. Dottorini ME, Lomuscio G, Mazzucchelli L, et al. Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. Journal of Nuclear Medicine. 1995;36:21–27
  33. Yamamoto Y, Nishiyama Y, Monden T, et al. Clinical usefulness of fusion of 131I SPECT and CT images in pateints with differentiated thyroid carcinoma. Journal of Nuclear Medicine. 2003;44:1905–1910
  34. Tharp K, Israel O, Hausmann J, et al. Impact of 131I-SPECT/CT images obtained with an integrated system in the follow-up of patients with thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:1435–1442
  35. Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. The Journal of Clinical Endocrinology and Metabolism. 2006;91:2892–2899
  36. van Nostrand D, Atkins F, Yeganeh F, et al. Dosimetrically determined doses of radioiodine for the treatment of metastatic thyroid carcinoma. Thyroid. 2002;12:121–134
  37. Dorn R, Kopp J, Vogt H, et al. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. Journal of Nuclear Medicine. 2003;44:451–460
  38. Tuttle RM, Leboeuf R, Robbins RJ, et al. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer. Journal of Nuclear Medicine. 2006;47:1587–1591Erratum in: J Nucl Med. 2007; 48: 7
  39. Ilgan S, Karacalioglu AO, Pabuscu Y, et al. Iodine-131 treatment and high-resolution CT: results in patients with lung metastases from differentiated thyroid carcinoma. European Journal of Nuclear Medicine and Molecular Imaging. 2004;3:825–830
  40. Ronga G, Filesi M, Montesano T, et al. Lung metastases from differentiated thyroid carcinoma. A 40 years' experience. The Quarterly Journal of Nuclear Medicine and Molecular Imaging. 2004;48:12–19
  41. Schlumberger M, Challeton C, De Vathaire F, et al. Radioactive iodine treatment for lung and bone metastases from thyroid carcinoma. Journal of Nuclear Medicine. 1996;37:598–605
  42. Reiners C. Radioiodine therapy in patients with pulmonary metastases of thyroid cancer: when to treat, when not to treat?. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:939–942
  43. Bernier MO, Leenhardt L, Hoang C, et al. Survival and therapeutic modalities in patients with bone metastases of differentiated thyroid carcinomas. The Journal of Clinical Endocrinology and Metabolism. 2001;86:1568–1573
  44. Zettinig G, Fueger BJ, Passler C, et al. Long-term follow-up of patients with bone metastases from differentiated thyroid carcinoma – surgery or conventional therapy?. Clinical Endocrinology. 2002;56:377–382
  45. Chiu AC, Delpassand ES, Sherman SI. Prognosis and treatment of brain metastases in thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 1997;82:3637–3642
  46. McWilliams RR, Giannini C, Hay ID, et al. Management of brain metastases from thyroid carcinoma: a study of 16 histopathologically confirmed cases over 25 years. Cancer. 2003;98:356–362
  47. Luster M, Lippi F, Jarzab B, et al. rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocrine-Related Cancer. 2005;12:49–64
  48. de Keizer B, Brans B, Hoekstra A, et al. Tumour dosimetry and response in patients with metastatic differentiated thyroid cancer using recombinant human thyrotropin before radioiodine therapy. European Journal of Nuclear Medicine and Molecular Imaging. 2003;30:367–373
  49. Pötzi C, Moameni A, Karanikas G, et al. Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clinical Endocrinology. 2006;65:519–523
  50. Braga M, Ringel MD, Cooper DS. Sudden enlargement of local recurrent thyroid tumor after recombinant human TSH administration. The Journal of Clinical Endocrinology and Metabolism. 2001;86:5148–5151
  51. Liu YY, van der Pluijm G, Karperien M, et al. Lithium as adjuvant to radioiodine therapy in differentiated thyroid carcinoma: clinical and in vitro studies. Clinical Endocrinology. 2006;64:617–624
  52. Koong SS, Reynolds JC, Movius EG, et al. Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. The Journal of Clinical Endocrinology and Metabolism. 1999;84:912–916
  53. Börner AR, Petrich T, Weckesser E, et al. Monitoring isotretinoin therapy in the thyroid cancer using 18F-FDG-PET. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29:231–236
  54. Grüning T, Tiepolt C, Zöphel K, et al. Retinoid acid for redifferentiation of thyroid cancer – does it hold its promise?. European Journal of Endocrinology. 2003;148:395–402
  55. Simon D, Korber C, Krausch M, et al. Clincal impact of retinoids in redifferentiation therapy of advanced thyroid cancer: final results of a pilot study. European Journal of Nuclear Medicine and Molecular Imaging. 2002;29:775–782
  56. Oyen WJG, Bodei L, Giammarile F, et al. Targeted therapy in nuclear medicine – current status and future prospects. Annals of Oncology. 2007;18:1782–1792
  57. Haugen BR. Redifferentiation therapy in advanced thyroid cancer. Current Drug Targets. Immune, Endocrine and Metabolic Disorders. 2004;4:175–180
  58. Schmutzler C. Regulation of the sodium/iodine symporter by retinoids – a review. Experimental and Clinical Endocrinology & Diabetes. 2001;109:41–44
  59. Liu YY, Stokkel MP, Morreau HA, et al. Radioiodine therapy after pre-treatment with bexarotene for metastases of differentiated thyroid carcinoma. Clinical Endocrinology. 2008;68:605–609
  60. Schlumberger M, Mancusi F, Baudin E, et al. 131-I therapy for elevated thyroglobulin levels. Thyroid. 1997;7:273–276
  61. Pineda JD, Lee T, Ain K, et al. Iodine-131 therapy for thyroid cancer patients with elevated thyroglobulin and negative diagnostic scan. The Journal of Clinical Endocrinology and Metabolism. 1995;80:1488–1492
  62. Pacini F, Agate L, Elisei R, et al. Outcome of differentiated thyroid cancer with detectable serum thyroglobulin and negative diagnostic (131)I whole body scan: comparison of patients treated with high (131)I activities versus untreated patients. The Journal of Clinical Endocrinology and Metabolism. 2001;86:4092–4097
  63. van Tol KM, Jager PL, de Vries EG, et al. Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin. European Journal of Endocrinology. 2003;148:589–596
  64. Kabasakal L, Selcuk NA, Shafipour H, et al. Treatment of iodine-negative thyreoglobulin-positive thyroid cancer: differences in outcome in patients with macrometastases and patients with micrometastases. European Journal of Nuclear Medicine and Molecular Imaging. 2004;31:1500–1504
  65. Leboulleux S, Schroeder PR, Schlumberger M, et al. The role of PET in follow-up of patients treated for differentiated epithelial thyroid cancers. Nature Clinical Practice. Endocrinology & Metabolism. 2007;3:112–121
  66. Zoller M, Kohlfuerst S, Igerc I, et al. Combined PET/CT in the follow-up of differentiated thyroid carcinoma: what is the impact of each modality?. European Journal of Nuclear Medicine and Molecular Imaging. 2007;34:487–495
  67. Rubino C, de Vathaire F, Dottorini ME, et al. Second primary malignancy in thyroid cancer patients. British Journal of Cancer. 2003;89:1638–1644
  68. Bhattacharyya N, Chien W. Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. The Annals of Otology, Rhinology, and Laryngology. 2006;115:607–610
  69. Alexander C, Bader JB, Schäfer A, et al. Intermediate and long-termn side effects of high-dose radioiodine therapy for thyroid carcinoma. Journal of Nuclear Medicine. 1998;39:1551–1554

PII: S1521-690X(08)00110-3

doi: 10.1016/j.beem.2008.09.013

Best Practice & Research Clinical Endocrinology & Metabolism
Volume 22, Issue 6 , Pages 989-1007 , December 2008

Article Tools

* Image Usage & Resolution